Seth Rosen, MD
Hematology & Oncology · Port St Lucie, FLNPI 1740398262
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.2% of the total across 579 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 58 manufacturers, the largest accounting for just 8.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,435 and has fallen 69.7% since, to $1,041 in 2025.
Across 579 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$852
- Amgen$835
- AstraZeneca$674
- Genentech USA, Inc.$600
- AbbVie$575
- Pfizer$568
- plus $7K from 52 others
Across 366 payments — averaging $14,931 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alkermes, Inc.$4.4M
- Array Biopharma Inc$697K
- Merck$206K
- Incyte Corporation$127K
- Genentech, Inc.$2K
What the payments were for
- Food & beverage$9,95293%
- Education$7227%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NINLARO$223
- Kyprolis$125
- SpaceOAR VUE System - 10mL$114
- BRAFTOVI$103
- MEKTOVI$103
How this compares
$10,674 in reported general payments places this provider in the 60th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 57 | $923,004 |
| CalquenceAcalabrutinib Maleate | 65 | $869,714 |
| PomalystPomalidomide | 35 | $823,498 |
| BrukinsaZanubrutinib | 36 | $529,627 |
| XtandiEnzalutamide | 36 | $516,913 |
| ErleadaApalutamide | 29 | $401,144 |
| Lupron DepotLeuprolide Acetate | 52 | $316,505 |
| OjjaaraMomelotinib Dihydrochloride | 11 | $316,485 |
| PromactaEltrombopag Olamine | 24 | $271,994 |
| FruzaqlaFruquintinib | 11 | $268,335 |
| RevlimidLenalidomide | 13 | $228,750 |
| VerzenioAbemaciclib | 13 | $200,731 |
| Lenalidomide | 14 | $173,222 |
| ProcritEpoetin Alfa | 55 | $165,064 |
| NubeqaDarolutamide | 11 | $150,073 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $75 | $923,00457 claims |
| AstraZenecaCalquence | $674 | $869,71465 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $320 | $823,49835 claims |
| Johnson & JohnsonErleada, Procrit, Xarelto | $852 | $630,725153 claims |
| Beigene USA, Inc.Brukinsa | $40 | $529,62736 claims |
| Astellas Pharma US IncXtandi | $228 | $516,91336 claims |
| AbbVieLupron Depot | $575 | $316,50552 claims |
| GSKOjjaara | $237 | $316,48511 claims |
| NovartisPromacta | $369 | $271,99424 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Fruzaqla | $538 | $268,33511 claims |
| Bristol Myers SquibbRevlimid | $176 | $228,75013 claims |
| Lilly USA, LLCVerzenio | $151 | $200,73113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Port St Lucie
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
- Daniel LandauOrlando$1.8M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
- Steven FeinMiami$1M
- Vamsidhar VelchetiJacksonville$966K
- Shahram MoriOrlando$952K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.